European psychiatry : the journal of the Association of European Psychiatrists最新文献

{"title":"The PADRIS-PRESTO cohort: A comprehensive population-based study on mental health in Catalonia.","authors":"Michele De Prisco, Vincenzo Oliva, Giovanna Fico, Ariadna Mas, Clàudia Valenzuela-Pascual, Laura Montejo, Marta Bort, Constanza Sommerhoff, Analia Bortolozzi, Lluis Miquel-Rio, Elisabet Vilella, Maria Florencia Forte, Lydia Fortea, Tabatha Fernández, Anna Giménez-Palomo, Maria Sague Vilavella, Santiago Madero, Vicent Llorca Bofí, Miquel Bioque, Iria Grande, Andrea Murru, Isabella Pacchiarotti, Myriam Cavero, Jordi Blanch, Clara Viñas-Bardolet, Vicenç Aparicio-Nogué, Juan Francisco Martínez-Cerdá, Eduard Parellada, Anabel Martínez-Arán, Joaquim Radua, Eduard Vieta, Diego Hidalgo-Mazzei, Gerard Anmella","doi":"10.1192/j.eurpsy.2025.10103","DOIUrl":"10.1192/j.eurpsy.2025.10103","url":null,"abstract":"<p><strong>Background: </strong>Mental disorders affect nearly 970 million people worldwide, impacting individuals and healthcare systems. Large population databases offer insights often unattainable in smaller studies, but their findings may not always generalize across diverse regions. To address this, we introduce a European cohort from Catalonia, Spain, allowing for comparisons between individuals with mental disorders and the general population.</p><p><strong>Methods: </strong>Data were obtained from the \"Programa <i>d</i>'analítica de dades per a la recerca i la innovació en salut\" (PADRIS). The cohort included all individuals who accessed public specialized mental health services between 2015 and 2019, with retrospective follow-up extending to 2010. These individuals, referred to as cases, were matched by age, sex, and health region with controls, individuals who had no interactions with mental health services during the same period. Sociodemographic and clinical characteristics, including psychiatric diagnoses, comorbidities, smoking status, healthcare utilization, and prescribed treatments, were analyzed.</p><p><strong>Results: </strong>The study included 1,421,510 individuals (mean age: 41.6±22.1; 53.6% female), with 473,812 cases and 947,698 controls. Cases were more likely to be exempt from income reporting, be ever-smokers, and have musculoskeletal comorbidities. A total of 1,547,374 psychiatric diagnoses were recorded, with anxiety (31.38%) and mood disorders (18.83%) being the most frequent. Over the follow-up, 76.2 million primary care visits and 67.1 million prescriptions were recorded.</p><p><strong>Conclusions: </strong>This cohort enhances our understanding of mental health service use, diagnostic trends, and treatment patterns in Catalonia. The insights derived from this cohort have the potential to inform mental health policies, improving outcomes within and beyond the region.</p>","PeriodicalId":520621,"journal":{"name":"European psychiatry : the journal of the Association of European Psychiatrists","volume":" ","pages":"e144"},"PeriodicalIF":6.7,"publicationDate":"2025-09-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12538175/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145088865","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Prevalence of posttraumatic stress symptoms among physicians - A meta-analysis.","authors":"Jana Reinhardt, Katja Linde, Anette Kersting","doi":"10.1192/j.eurpsy.2025.10084","DOIUrl":"10.1192/j.eurpsy.2025.10084","url":null,"abstract":"<p><strong>Background: </strong>The medical profession is associated with high demands and occupational stressors - including confrontation with illness and death, extended work hours, and high workload - which may increase the risk of traumatization and posttraumatic stress disorder (PTSD). This systematic review aimed to synthesize evidence on prevalence of PTSD among physicians and examine potential moderators, including the COVID-19 pandemic, specialties, and geographic regions.</p><p><strong>Methods: </strong>A systematic search was conducted in PubMed, Web of Science, PsychINFO, and PubPsych up to April 2025. Included studies were English-language, peer-reviewed, observational studies, reporting PTSD prevalence in physicians, using validated instruments. Studies focusing on preselected PTSD cases or mixed healthcare samples were excluded. Data extraction included study methodology, measurement tools, geographic region, specialty, and survey timing (pre-/\"post\"-COVID). Risk of bias was assessed using the <i>JBI critical appraisal checklist for prevalence studies.</i> Quantitative synthesis and moderator analyses were performed. The review was registered with PROSPERO (ID CRD42023401984).</p><p><strong>Results: </strong>Based on 81 studies (<i>N</i> = 41,051), the pooled PTSD prevalence using a random-effects model was 14.9% (95% CI [0.132-0.168]). Prevalence estimates were lower in high-income (13.6%) compared to middle-income countries (21.1%) (<i>p</i> < 0.036). Studies employing brief screening tools (≤10 items) yielded significantly lower prevalence estimates (10.2%) than those using longer instruments (16.4%) (<i>p</i> < 0.027). No other significant moderators were identified.</p><p><strong>Conclusion: </strong>PTSD prevalence among physicians is elevated relative to the general population, with notable variation across regions and measurement approaches. Future research should address gaps in representativeness and geographic coverage to improve prevalence estimates and guide prevention strategies.</p>","PeriodicalId":520621,"journal":{"name":"European psychiatry : the journal of the Association of European Psychiatrists","volume":"68 1","pages":"e132"},"PeriodicalIF":6.7,"publicationDate":"2025-09-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12538191/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145088872","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Self-harming behavior linked to earlier onset of cardiovascular disease in severe mental disorders.","authors":"Synve Hoffart Lunding, Isabel Viola Kreis, Linn Rødevand, Monica Aas, Maren Caroline Frogner Werner, Ingrid Torp Johansen, Monica Bettina Elkjær Greenwood Ormerod, Elina Reponen, Gabriela Hjell, Petter Andreas Ringen, Trine Vik Lagerberg, Ingrid Melle, Ole Andreas Andreassen, Carmen Simonsen, Torill Ueland, Nils Eiel Steen","doi":"10.1192/j.eurpsy.2025.10106","DOIUrl":"10.1192/j.eurpsy.2025.10106","url":null,"abstract":"<p><strong>Background: </strong>People with severe mental disorders (SMDs) have about 15 years shorter life expectancy than the general population. Cardiovascular disease (CVD) is among the leading causes of premature mortality and shares genetic underpinnings with SMDs. We investigated the link between clinical traits in SMDs and time to the first CVD diagnosis.</p><p><strong>Methods: </strong>The study included 1,627 well-characterized participants with schizophrenia spectrum (SCZ, <i>N</i> = 998) and bipolar spectrum disorders (BDs, <i>N</i> = 629), and a reference group of 1,201 healthy controls. CVD diagnoses were obtained from two Norwegian national registries (covering both primary and specialist health care) for the period of 2006-2020. Applying Cox proportional hazard models, we investigated associations between SMD clinical traits and time to first CVD diagnosis in SMD participants, adjusting for age, sex, diagnosis, and tobacco use.</p><p><strong>Results: </strong>Among individuals with SMD, recurring self-harming behavior (SHB) was associated with a shorter time to first CVD diagnosis (<i>p</i> = .029) relative to those without SHB. In the subgroup with SHB and a history of attempted suicide(s), more suicide attempts were associated with shorter time to first CVD diagnosis (<i>p</i> = .041). Significant associations of time to first CVD diagnosis with age at SMD onset and comorbid substance use disorder were not demonstrated.</p><p><strong>Conclusions: </strong>SHB and a history of suicide attempts in individuals with SMD seem to be associated with earlier CVD onset, and may improve the prediction of CVD, in addition to standard cardiovascular risk factors.</p>","PeriodicalId":520621,"journal":{"name":"European psychiatry : the journal of the Association of European Psychiatrists","volume":" ","pages":"e143"},"PeriodicalIF":6.7,"publicationDate":"2025-09-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12538181/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145067585","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Disease progression in bipolar disorder in relation to white matter microstructure: A comprehensive approach based on staging models.","authors":"Katharina Thiel, Kira Flinkenflügel, Dominik Grotegerd, Christoph Jurischka, Julia Hubbert, Tim Hahn, Elisabeth J Leehr, Hannah Meinert, Elisabeth Schrammen, Florian Thomas-Odenthal, Paula Usemann, Lea Teutenberg, Benjamin Straube, Nina Alexander, Hamidreza Jamalabadi, Andreas Jansen, Frederike Stein, Michael Bauer, Andrea Pfennig, Eva Mennigen, Philipp Kanske, Katharina Förster, Igor Nenadić, Tilo Kircher, Susanne Meinert, Udo Dannlowski","doi":"10.1192/j.eurpsy.2025.10105","DOIUrl":"10.1192/j.eurpsy.2025.10105","url":null,"abstract":"<p><strong>Background: </strong>Bipolar disorder (BD) is assumed to follow a progressive course, conceptualized through staging models. It is unclear whether white matter (WM) microstructure abnormalities, central to BD pathophysiology, parallel this development throughout disease progression. This study explored the link between WM and disease progression in BD, using a comprehensive approach based on clinical staging models.</p><p><strong>Methods: </strong>This cross-sectional diffusion tensor-imaging study included 153 BD patients and 153 healthy controls (HCs) matched for age, sex, and study site. Using tract-based spatial statistics (TBSS), we examined associations between WM integrity and three criteria: (1) number of manic episodes, (2) remission quality between episodes, and (3) inter-episode global functioning.</p><p><strong>Results: </strong>Analyses revealed significant fractional anisotropy (FA) differences between early and late stages of BD based on the number of manic episodes (<i>p</i>_tfce-FWE = 0.003), but not on remission quality (<i>p</i>_tfce-FWE = 0.075). However, compared to HC, BD patients with persistent symptoms between episodes showed more widespread FA differences (<i>p</i>_tfce-FWE < 0.001) than those with stable remission (<i>p</i>_tfce-FWE = 0.031). Regression analyses indicated a positive association between global functioning and FA in euthymic BD patients (<i>p_tfce-FWE</i> < 0.001).</p><p><strong>Conclusions: </strong>Results indicated more severe WM disruptions in patients at advanced stages compared to earlier stages of the disease. While these findings may imply changes occurring with disease progression, the cross-sectional design cannot rule out that they instead reflect stable clinical subtypes of varying severity. The results highlight the clinical relevance of WM alterations and the need for longitudinal studies to better understand the neurobiology and complexity of BD.</p>","PeriodicalId":520621,"journal":{"name":"European psychiatry : the journal of the Association of European Psychiatrists","volume":" ","pages":"e148"},"PeriodicalIF":6.7,"publicationDate":"2025-09-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12538178/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145067569","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Minor immunomodulatory effects of psychotropics suggested in severe mental disorders: Associations of antipsychotics with beta defensin 2, antidepressants with C-reactive protein, and mood stabilizers with soluble interleukin 2 receptor.","authors":"Monica B E G Ormerod, Mashhood A Sheikh, Thor Ueland, Gabriela Hjell, Linn Rødevand, Linn Sofie Sæther, Synve Hoffart Lunding, Ingrid Torp Johansen, Dimitrios Andreou, Torill Ueland, Trine Vik Lagerberg, Ingrid Melle, Srdjan Djurovic, Ole A Andreassen, Nils Eiel Steen","doi":"10.1192/j.eurpsy.2025.10104","DOIUrl":"10.1192/j.eurpsy.2025.10104","url":null,"abstract":"<p><strong>Background: </strong>Immunomodulatory effects of psychotropic agents used to treat severe mental disorders (SMDs) have been suggested. We investigated associations between immune marker levels and antipsychotic- (AP), antidepressant- (AD), and mood stabilizing agents (MS) use in SMDs.</p><p><strong>Methods: </strong>We included 1215 participants with SMDs (777 with schizophrenia spectrum disorders and 438 with bipolar disorders). Circulating levels of 45 immune markers were determined by enzyme-immunoassay or immunoturbidimetry and analyzed for associations with use, doses, and serum concentrations of AP, AD, and MS. Extensive adjustments for potential confounders were performed. Immune marker levels of 1008 healthy controls served as a reference.</p><p><strong>Results: </strong>AP use was significantly associated with higher plasma levels of beta defensin 2 (BD-2) (<i>β</i> = 0.094, <i>p</i> = 0.8E-4), AD use with higher serum levels of CRP (<i>β</i> = 0.072, <i>p</i> = 0.8E-3), and MS use with higher plasma levels of soluble interleukin 2 receptor (sIL-2R) (<i>β</i> = 0.063, <i>p</i> = 0.9E-4). These findings were paralleled by positive associations with psychotropic agent dose and serum concentrations: AP dose was associated with BD-2 levels (<i>β</i> = 0.045, <i>p</i> = 2.3E-4), AD dose with CRP levels (<i>β</i> = 0.039, <i>p</i> = 0.001), MS dose with sIL-2R levels (<i>β</i> = 0.048, <i>p</i> = 0.001), and serum concentration of AD was nominally positively associated with CRP (<i>β</i> = 0.072, <i>p</i> = 0.002).</p><p><strong>Conclusions: </strong>The findings suggest that AP and MS use affect pathways involved in immune homeostasis and inflammatory regulation in individuals with SMDs, while AD use augments low-grade systemic inflammation reflected by CRP.</p>","PeriodicalId":520621,"journal":{"name":"European psychiatry : the journal of the Association of European Psychiatrists","volume":" ","pages":"e140"},"PeriodicalIF":6.7,"publicationDate":"2025-09-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12538189/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145042893","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Long-lasting effects on cognition and mental health in patients with post COVID-19 condition following a mild SARS-CoV-2 infection: A longitudinal case-control study.","authors":"Goran Papenberg, Marika C Möller, Gabriela Markovic, Kristian Borg, Jonas Stenberg, Stina Hedström, Frida Smids, Emil Norrman, Andrea Aejmelaeus-Lindström, Grégoria Kalpouzos, Erika J Laukka","doi":"10.1192/j.eurpsy.2025.10108","DOIUrl":"10.1192/j.eurpsy.2025.10108","url":null,"abstract":"<p><strong>Background: </strong>The prevalence of prolonged symptoms following a severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection represents a significant health challenge with potentially severe individual and societal costs. Our study investigates the long-term cognitive and mental health consequences associated with post-coronavirus disease 2019 (COVID-19) condition (PCC) following a mild SARS-CoV-2 infection.</p><p><strong>Methods: </strong>We conducted longitudinal assessments of cognitive performance and mental health in 50 post-COVID-19 patients and 48 matched healthy controls across 10 months, starting on average 2 years after infection. Cognitive function was evaluated using a comprehensive neuropsychological battery of standardized tests, while mental health was assessed via self-reported questionnaires. Data were analyzed with linear mixed models.</p><p><strong>Results: </strong>Initial group differences in cognitive performance were observed for memory, executive functioning, and perceptual speed, with worse performance in patients. Improvement across the follow-up period occurred for most tasks, with PCC patients displaying greater improvement compared to healthy controls for some memory and executive function tasks, reaching performance levels of the control group. Fatigue and mental health measures remained elevated in the patient group, with worsening in general fatigue and a small improvement in fatigue after cognitive testing. Factors such as male sex, absence of burnout history, and lower depression scores at baseline predicted cognitive recovery in the patient group.</p><p><strong>Conclusions: </strong>Our study underscores the importance of addressing cognitive and psychological effects following mild SARS-CoV-2 infection, as persistent fatigue, low mental health, and cognitive impairments significantly impact individuals' ability to return to their pre-COVID professional and personal lives.</p>","PeriodicalId":520621,"journal":{"name":"European psychiatry : the journal of the Association of European Psychiatrists","volume":" ","pages":"e141"},"PeriodicalIF":6.7,"publicationDate":"2025-09-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12538188/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145042904","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Pre- and postnatal maternal depressive symptoms associated with local connectivity of the left amygdala in 5-year-olds.","authors":"Elena Vartiainen, Anni Copeland, Elmo P Pulli, Venla Kumpulainen, Eero Silver, Olli Rajasilta, Ashmeet Jolly, Silja Luotonen, Hilyatushalihah K Audah, Niloofar Hashempour, Wajiha Bano, Ilkka Suuronen, Ekaterina Saukko, Suvi Häkkinen, Hasse Karlsson, Linnea Karlsson, Jetro J Tuulari","doi":"10.1192/j.eurpsy.2025.10097","DOIUrl":"10.1192/j.eurpsy.2025.10097","url":null,"abstract":"<p><strong>Background: </strong>Maternal depressive symptoms can influence brain development in offspring, prenatally through intrauterine programming, and postnatally through caregiving related mother-child interaction.</p><p><strong>Methods: </strong>The participants were 5-year-old mother-child dyads from the FinnBrain Birth Cohort Study (<i>N</i> = 68; 28 boys, 40 girls). Maternal depressive symptoms were assessed with the Edinburgh Postnatal Depression Scale (EPDS) at gestational week 24, 3 months, 6 months, and 12 months postnatal. Children's brain imaging data were acquired with task-free functional magnetic resonance imaging (fMRI) at the age of 5 years in 7-min scans while watching the <i>Inscapes</i> movie. The derived brain metrics included whole-brain regional homogeneity (ReHo) and seed-based connectivity maps of the bilateral amygdalae.</p><p><strong>Results: </strong>We found that maternal depressive symptoms were positively associated with ReHo values of the left amygdala. The association was highly localized and strongest with the maternal depressive symptoms at 3 months postnatal. Seed-based connectivity analysis did not reveal associations between distal connectivity of the left amygdala region and maternal depressive symptoms.</p><p><strong>Conclusions: </strong>These results suggest that maternal depressive symptoms soon after birth may influence offspring's neurodevelopment in the local functional coherence in the left amygdala. They underline the potential relevance of postnatal maternal distress exposure on neurodevelopment that has received much less attention than prenatal exposures. These results offer a possible thus far understudied pathway of intergenerational effects of perinatal depression that should be further explored in future studies.</p>","PeriodicalId":520621,"journal":{"name":"European psychiatry : the journal of the Association of European Psychiatrists","volume":" ","pages":"e130"},"PeriodicalIF":6.7,"publicationDate":"2025-09-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12538180/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145002741","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Effectiveness of a peer-facilitated, recovery-focused self-illness management program for adults with first-episode psychosis: A randomized controlled trial.","authors":"Wai Tong Chien, Ka Ming Chow, Richard J Gray, Cecilia W McMaster","doi":"10.1192/j.eurpsy.2025.10093","DOIUrl":"10.1192/j.eurpsy.2025.10093","url":null,"abstract":"<p><strong>Background: </strong>Psychosocial interventions for people with mental illness are increasingly focusing on facilitating recovery and self-care. Despite evidence from Europe on the short-term effects of recovery self-planning programs for people discharged from crisis resolution teams, similar programs and supporting evidence in other countries or healthcare contexts are lacking, particularly regarding cultural adaptation and long-term assessment. This randomized controlled trial compared a 4-month peer-facilitated, recovery-focused self-illness management (Peer-RESIM) program for Chinese adults with first-episode psychosis with psychoeducation (PE) and treatment as usual (TAU).</p><p><strong>Methods: </strong>Patients (<i>N</i> = 198) were recruited from four Integrated Community Centres for Mental Wellness in Hong Kong and randomly assigned to the Peer-RESIM, PE, or TAU group (66/group). The primary outcomes were recovery and functioning levels; the secondary outcomes were psychotic symptoms, problem-solving ability, rehospitalization rate, and service satisfaction. Assessments were conducted at baseline and immediate, 9, and 18 months postintervention.</p><p><strong>Results: </strong>The generalized estimating equation test revealed that the Peer-RESIM group reported significantly greater improvements in recovery, functioning, problem-solving ability, psychotic symptoms, average duration of rehospitalizations, and service satisfaction (<i>p</i> = 0.01-0.04, small to large effect sizes) than the TAU group at all three posttests and the PE group at 18 months postintervention.</p><p><strong>Conclusions: </strong>The Peer-RESIM can enhance long-term recovery and self-care in adults with early-stage psychosis.</p>","PeriodicalId":520621,"journal":{"name":"European psychiatry : the journal of the Association of European Psychiatrists","volume":" ","pages":"e131"},"PeriodicalIF":6.7,"publicationDate":"2025-09-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12538176/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145002712","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Perimenopausal symptoms in women with and without ADHD: A population-based cohort study.","authors":"Unnur Jakobsdóttir Smári, Unnur Anna Valdimarsdottir, Dora Wynchank, Maxime de Jong, Thor Aspelund, Arna Hauksdottir, Edda Bjork Thordardottir, Gunnar Tomasson, Johanna Jakobsdottir, Donghao Lu, Alicia Nevriana, Henrik Larsson, Sandra Kooij, Helga Zoega","doi":"10.1192/j.eurpsy.2025.10101","DOIUrl":"10.1192/j.eurpsy.2025.10101","url":null,"abstract":"<p><strong>Background: </strong>Knowledge of the impact of perimenopause on women with attention-deficit/hyperactivity disorder (ADHD) is lacking. We compared levels of perimenopausal symptoms and prevalence of severe perimenopausal symptoms among women with and without ADHD across age groups.</p><p><strong>Methods: </strong>In this cohort study, we used data from the population-based Stress-and-Gene-Analysis cohort study. ADHD diagnosis was self-reported at baseline and 5-year follow-up. At follow-up, we assessed ADHD symptoms using the Adult ADHD Self-Report Scale, perimenopausal symptoms (psychological, somatic, and urogenital) using Menopause Rating Scale (MRS), and general physical symptoms using Patient Health Questionnaire. We described mean scores and mean difference on MRS among women with and without ADHD with linear regression models and contrasted the prevalence of severe perimenopausal symptoms among women with and without ADHD, calculating prevalence ratios (PRs) with 95% confidence intervals (CIs) using modified Poisson regression models.</p><p><strong>Results: </strong>Women with ADHD (<i>n</i> = 535) had higher total perimenopausal symptom scores (18.0 vs. 13.0, <i>p</i> < 0.01) than women without ADHD (<i>n</i> = 4,857). The difference was most pronounced among women aged 35-39 years (19.0 vs. 12.5, <i>p</i> < 0.01). The prevalence of severe perimenopausal symptoms was significantly higher among women with ADHD compared to those without, both overall (54.2% vs. 30.1%, PR = 1.80, 95% CI = 1.64-1.98) and on all subdimensions (psychological: 58.6% vs. 36.0%, PR = 1.63, 95% CI = 1.51-1.76; somatic: 30.4% vs. 13.9%, PR = 2.20, 95% CI = 1.88-2.57; uro-genital: 43.2% vs. 27.5%, PR = 1.57, 95% CI = 1.40-1.77).</p><p><strong>Conclusion: </strong>Women with ADHD have higher prevalence of severe perimenopausal symptoms. These symptoms present at an earlier age than among women without ADHD, indicating an earlier onset age of perimenopause in ADHD.</p>","PeriodicalId":520621,"journal":{"name":"European psychiatry : the journal of the Association of European Psychiatrists","volume":" ","pages":"e133"},"PeriodicalIF":6.7,"publicationDate":"2025-09-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12538516/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144995003","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Benzodiazepine use and multidimensional health burden in severe psychiatric disorders: Impaired quality of life, metabolic comorbidities, and adverse effects in a large cross-sectional study.","authors":"Vincent Achour, Mélanie Faugere, Eloïse Maakaron, Jonathan Gavat, Guillaume Fond, Christophe Lançon, Théo Korchia","doi":"10.1192/j.eurpsy.2025.10098","DOIUrl":"10.1192/j.eurpsy.2025.10098","url":null,"abstract":"<p><strong>Background: </strong>Benzodiazepines (BZ) are widely prescribed to patients with severe mental illnesses, yet their long-term impact on global health remains underinvestigated. While their symptomatic benefits are acknowledged, data on their associations with quality of life (QoL), metabolic comorbidities, and side effects are limited.</p><p><strong>Methods: </strong>In this cross-sectional study, we analyzed clinical data from 1,248 patients with schizophrenia, bipolar disorder (BD), or major depressive disorder at a psychiatric center in Marseille, France. Associations between BZ use and key outcomes - including QoL (Short Form Health Survey [SF-36], EuroQol-5 Dimensions [EQ-5D], and Schizophrenia Quality of Life Questionnaire - 18 items [SQoL-18]), metabolic parameters, and treatment side effects (Udvalg for Kliniske Undersøgelser Side Effect Rating Scale [UKU scale]) - were examined using multivariate regression analyses.</p><p><strong>Results: </strong>BZ use was significantly associated with lower QoL scores on physical and mental health domains of the SF-36 (<i>p</i> < 0.001), increased impairment across EQ-5D dimensions, and reduced subjective well-being (SQoL-18, <i>p</i> = 0.043). BZ users also presented higher rates of obesity, diabetes, and metabolic syndrome (all <i>p</i> < 0.05). Furthermore, BZ use was independently associated with a higher burden of side effects across UKU subscales, particularly in the psychiatric domain (emotional blunting, anxiety, and depressive symptoms; <i>p</i> = 0.003).</p><p><strong>Conclusion: </strong>These findings suggest that BZ use in severe psychiatric disorders may be linked to a substantial multidimensional health burden, including reduced QoL, greater side effect profile, and increased metabolic risk. These results highlight the need for evaluation of long-term BZ use and the promotion of safer alternative treatments.</p>","PeriodicalId":520621,"journal":{"name":"European psychiatry : the journal of the Association of European Psychiatrists","volume":" ","pages":"e134"},"PeriodicalIF":6.7,"publicationDate":"2025-09-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12538170/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144986268","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}